MARKET

GLMD

GLMD

Galmed Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.17
-0.18
-2.83%
Closed 16:00 02/21 EST
OPEN
6.37
PREV CLOSE
6.35
HIGH
6.39
LOW
6.11
VOLUME
59.95K
TURNOVER
--
52 WEEK HIGH
9.37
52 WEEK LOW
3.418
MARKET CAP
130.34M
P/E (TTM)
-8.1961
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of GLMD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GLMD stock price target is 25.33 with a high estimate of 35.00 and a low estimate of 10.00.

EPS

GLMD News

More
  • NASH: The Second Wave
  • Seeking Alpha - Article · 2d ago
  • 13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market
  • Benzinga · 02/05 21:11
  • 13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market
  • Benzinga · 02/05 21:11
  • Benzinga's Top Upgrades, Downgrades For February 4, 2020
  • Benzinga · 02/04 14:48

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About GLMD

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.
More

Webull offers kinds of Galmed Pharmaceuticals Ltd stock information, including NASDAQ:GLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLMD stock news, and many more online research tools to help you make informed decisions.